GlassScriptPhysician profile
Ulrich Berg
NPI 1760400667
$8,745.29
in general payments reported to CMS, 2019-2025
12 companies · $1,091 in 2025
The $1,091 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,525 · 2020: $515 · 2021: $1,832 · 2022: $1,202 · 2023: $1,112 · 2024: $1,469 · 2025: $1,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,665 · Education: $5.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,665.39 |
| Education | $5.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,748.49 | 2021-2024 | Vraylar |
| Axsome Therapeutics, INC. | $1,540.09 | 2023-2025 | Auvelity |
| Lundbeck LLC | $1,320.65 | 2019-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $1,155.69 | 2019-2022 | |
| Allergan, INC. | $764.04 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $737.31 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $659.14 | 2019-2024 | Rexulti |
| Shire North American Group INC | $364.94 | 2019 | |
| Sunovion Pharmaceuticals INC. | $325.04 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $89.21 | 2023 | Latuda |
| Jazz Pharmaceuticals INC. | $21.97 | 2021 | |
| Merck Sharp & Dohme LLC | $18.72 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ulrich Berg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.